Scilight Press

Author Information

Received: 15 Mar 2026 | Revised: 06 Jun 2026 | Accepted: 06 Jul 2026 | Published: 24 Aug 2026

Abstract

Graphical Abstract

Image Viewer

Open in new tab

Download Image

Keywords

type 2 diabetes | sarcopenia | pyroptosis | HMGB1 | exercise intervention

References 

• 1.

  Hoogwerf, B.J. Diabetes and Sarcopenia: Intersection of Co Morbid Conditions. OBM Geriatr. 2025, 9, 299.

• 2.

  Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022, 183, 109119.

• 3.

  Qiao, Y.-S.; Chai, Y.-H.; Gong, H.-J.; Zhuldyz, Z.; Stehouwer, C.D.A.; Zhou, J.-B.; Simó, R. The Association Between Diabetes Mellitus and Risk of Sarcopenia: Accumulated Evidences From Observational Studies. Front. Endocrinol. 2021, 12, 782391.

• 4.

  de Luis Román, D.; Gómez, J.C.; García-Almeida, J.M.; Garrachón Vallo, F.; Guzmán Rolo, G.; López Gómez, J.J.; Tarazona-Santabalbina, F.J.; Sanz-Paris, A. Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes: Expert document. Rev. Endocr. Metab. Disord. 2024, 25, 651–661.

• 5.

  Lin, J.A.; Hou, J.D.; Wu, S.Y. Effect of Sarcopenia on Mortality in Type 2 Diabetes: A Long-Term Follow-Up Propensity Score-Matched Diabetes Cohort Study. J. Clin. Med. 2022, 11, 4424.

• 6.

  Park, S.W.; Goodpaster, B.H.; Strotmeyer, E.S.; Kuller, L.H.; Broudeau, R.; Kammerer, C.; de Rekeneire, N.; Harris, T.B.; Schwartz, A.V.; Tylavsky, F.A.; et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care 2007, 30, 1507–1512.

• 7.

  Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31.

• 8.

  Yeung, S.S.Y.; Reijnierse, E.M.; Pham, V.K.; Trappenburg, M.C.; Lim, W.K.; Meskers, C.G.M.; Maier, A.B. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2019, 10, 485–500.

• 9.

  Anagnostis, P.; Gkekas, N.K.; Achilla, C.; Pananastasiou, G.; Taouxidou, P.; Mitsiou, M.; Kenanidis, E.; Potoupnis, M.; Tsiridis, E.; Goulis, D.G. Type 2 Diabetes Mellitus is Associated with Increased Risk of Sarcopenia: A Systematic Review and Meta-analysis. Calcif. Tissue Int. 2020, 107, 453–463.

• 10.

  Huang, S.; Xiang, C.; Song, Y. Identification of the shared gene signatures and pathways between sarcopenia and type 2 diabetes mellitus. PLoS ONE 2022, 17, e0265221.

• 11.

  Chen, R.; Kang, R.; Tang, D. The mechanism of HMGB1 secretion and release. Exp. Mol. Med. 2022, 54, 91–102.

• 12.

  Murao, A.; Aziz, M.; Wang, H.; Brenner, M.; Wang, P. Release mechanisms of major DAMPs. Apoptosis 2021, 26, 152–162.

• 13.

  Qiao, R.; Guo, J.; Zhang, C.; Wang, S.; Fang, J.; Geng, R.; Kang, S.G.; Huang, K.; Tong, T. Diabetes-induced muscle wasting: molecular mechanisms and promising therapeutic targets. Crit. Rev. Food Sci. Nutr. 2025, 65, 4007–4023.

• 14.

  Li, X.; Xiao, G.Y.; Guo, T.; Song, Y.J.; Li, Q.M. Potential therapeutic role of pyroptosis mediated by the NLRP3 inflammasome in type 2 diabetes and its complications. Front. Endocrinol. 2022, 13, 986565.

• 15.

  Jin, H.; Xie, W.; He, M.; Li, H.; Xiao, W.; Li, Y. Pyroptosis and Sarcopenia: Frontier Perspective of Disease Mechanism. Cells 2022, 11, 1078.

• 16.

  Salom Vendrell, C.; García Tercero, E.; Moro Hernández, J.B.; Cedeno-Veloz, B.A. Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment. Nutrients 2023, 15, 4149.

• 17.

  Liu, Z.; Guo, Y.; Zheng, C. Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy. Front. Endocrinol. 2024, 15, 1375610.

• 18.

  Harrison, B.C.; Allen, D.L.; Leinwand, L.A. IIb or not IIb? Regulation of myosin heavy chain gene expression in mice and men. Skelet. Muscle 2011, 1, 5.

• 19.

  Oberbach, A.; Bossenz, Y.; Lehmann, S.; Niebauer, J.; Adams, V.; Paschke, R.; Schön, M.R.; Blüher, M.; Punkt, K. Altered fiber distribution and fiber-specific glycolytic and oxidative enzyme activity in skeletal muscle of patients with type 2 diabetes. Diabetes Care 2006, 29, 895–900.

• 20.

  Mogensen, M.; Sahlin, K.; Fernström, M.; Glintborg, D.; Vind, B.F.; Beck-Nielsen, H.; Højlund, K. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007, 56, 1592–1599.

• 21.

  Albers, P.H.; Pedersen, A.J.; Birk, J.B.; Kristensen, D.E.; Vind, B.F.; Baba, O.; Nøhr, J.; Højlund, K.; Wojtaszewski, J.F. Human muscle fiber type-specific insulin signaling: impact of obesity and type 2 diabetes. Diabetes 2015, 64, 485–497.

• 22.

  Tack, W.; De Cock, A.M.; Dirinck, E.L.; Bastijns, S.; Ariën, F.; Perkisas, S. Pathophysiological interactions between sarcopenia and type 2 diabetes: A two-way street influencing diagnosis and therapeutic options. Diabetes Obes. Metab. 2024, 26, 407–416.

• 23.

  Song, R.; Zhao, X.; Cao, R.; Liang, Y.; Zhang, D.Q.; Wang, R. Irisin improves insulin resistance by inhibiting autophagy through the PI3K/Akt pathway in H9c2 cells. Gene 2021, 769, 145209.

• 24.

  Yoshida, T.; Delafontaine, P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells 2020, 9, 1970.

• 25.

  Hirata, Y.; Nomura, K.; Senga, Y.; Okada, Y.; Kobayashi, K.; Okamoto, S.; Minokoshi, Y.; Imamura, M.; Takeda, S.; Hosooka, T.; et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight 2019, 4, e124952.

• 26.

  Sies, H.; Berndt, C.; Jones, D.P. Oxidative Stress. Annu. Rev. Biochem. 2017, 86, 715–748.

• 27.

  Tsalamandris, S.; Antonopoulos, A.S.; Oikonomou, E.; Papamikroulis, G.A.; Vogiatzi, G.; Papaioannou, S.; Deftereos, S.; Tousoulis, D. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur. Cardiol. 2019, 14, 50–59.

• 28.

  Yin, L.; Li, N.; Jia, W.; Wang, N.; Liang, M.; Yang, X.; Du, G. Skeletal muscle atrophy: From mechanisms to treatments. Pharmacol. Res. 2021, 172, 105807.

• 29.

  Trendelenburg, A.U.; Meyer, A.; Rohner, D.; Boyle, J.; Hatakeyama, S.; Glass, D.J. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 2009, 296, C1258–C1270.

• 30.

  Sartori, R.; Schirwis, E.; Blaauw, B.; Bortolanza, S.; Zhao, J.; Enzo, E.; Stantzou, A.; Mouisel, E.; Toniolo, L.; Ferry, A.; et al. BMP signaling controls muscle mass. Nat. Genet. 2013, 45, 1309–1318.

• 31.

  Winbanks, C.E.; Chen, J.L.; Qian, H.; Liu, Y.; Bernardo, B.C.; Beyer, C.; Watt, K.I.; Thomson, R.E.; Connor, T.; Turner, B.J.; et al. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J. Cell Biol. 2013, 203, 345–357.

• 32.

  Gan, Z.; Fu, T.; Kelly, D.P.; Vega, R.B. Skeletal muscle mitochondrial remodeling in exercise and diseases. Cell Res. 2018, 28, 969–980.

• 33.

  Axelrod, C.L.; Fealy, C.E.; Erickson, M.L.; Davuluri, G.; Fujioka, H.; Dantas, W.S.; Huang, E.; Pergola, K.; Mey, J.T.; King, W.T.; et al. Lipids activate skeletal muscle mitochondrial fission and quality control networks to induce insulin resistance in humans. Metabolism 2021, 121, 154803.

• 34.

  Mesinovic, J.; Zengin, A.; De Courten, B.; Ebeling, P.R.; Scott, D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab. Syndr. Obes. 2019, 12, 1057–1072.

• 35.

  Mesinovic, J.; Fyfe, J.J.; Talevski, J.; Wheeler, M.J.; Leung, G.K.W.; George, E.S.; Hunegnaw, M.T.; Glavas, C.; Jansons, P.; Daly, R.M.; et al. Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies. Diabetes Metab. J. 2023, 47, 719–742.

• 36.

  Fang, Y.; Tian, S.; Pan, Y.; Li, W.; Wang, Q.; Tang, Y.; Yu, T.; Wu, X.; Shi, Y.; Ma, P.; et al. Pyroptosis: A new frontier in cancer. Biomed. Pharmacother. 2020, 121, 109595.

• 37.

  Shi, J.; Gao, W.; Shao, F. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem. Sci. 2017, 42, 245–254.

• 38.

  Frank, D.; Vince, J.E. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019, 26, 99–114.

• 39.

  Lu, S.; Li, Y.; Qian, Z.; Zhao, T.; Feng, Z.; Weng, X.; Yu, L. Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Front. Immunol. 2023, 14, 1052756.

• 40.

  Hameed, I.; Masoodi, S.R.; Mir, S.A.; Nabi, M.; Ghazanfar, K.; Ganai, B.A. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J. Diabetes 2015, 6, 598–612.

• 41.

  Vandanmagsar, B.; Youm, Y.H.; Ravussin, A.; Galgani, J.E.; Stadler, K.; Mynatt, R.L.; Ravussin, E.; Stephens, J.M.; Dixit, V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17, 179–188.

• 42.

  Luo, B.; Li, B.; Wang, W.; Liu, X.; Xia, Y.; Zhang, C.; Zhang, M.; Zhang, Y.; An, F. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 2014, 9, e104771.

• 43.

  Ding, J.; Wang, K.; Liu, W.; She, Y.; Sun, Q.; Shi, J.; Sun, H.; Wang, D.C.; Shao, F. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 2016, 535, 111–116.

• 44.

  Wu, J.; Lin, S.; Chen, W.; Lian, G.; Wu, W.; Chen, A.; Sagor, M.I.H.; Luo, L.; Wang, H.; Xie, L. TNF-α contributes to sarcopenia through caspase-8/caspase-3/GSDME-mediated pyroptosis. Cell Death Discov. 2023, 9, 76.

• 45.

  Liu, M.; Li, L.; Dai, T.; Hou, Y.; Li, W.; Zhao, Y.; Fang, Q.; Yan, C. Gasdermine E-Dependent Mitochondrial Pyroptotic Pathway in Dermatomyositis: A Possible Mechanism of Perifascicular Atrophy. J. Neuropathol. Exp. Neurol. 2020, 79, 551–561.

• 46.

  Wang, L.; Jiao, X.F.; Wu, C.; Li, X.Q.; Sun, H.X.; Shen, X.Y.; Zhang, K.Z.; Zhao, C.; Liu, L.; Wang, M.; et al. Trimetazidine attenuates dexamethasone-induced muscle atrophy via inhibiting NLRP3/GSDMD pathway-mediated pyroptosis. Cell Death Discov. 2021, 7, 251.

• 47.

  Zhou, R.; Tardivel, A.; Thorens, B.; Choi, I.; Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2009, 11, 136–140.

• 48.

  Zhaolin, Z.; Guohua, L.; Shiyuan, W.; Zuo, W. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2019, 52, e12563.

• 49.

  Wajant, H.; Scheurich, P. TNFR1-induced activation of the classical NF-κB pathway. FEBS J. 2011, 278, 862–876.

• 50.

  Fang, W.Y.; Tseng, Y.T.; Lee, T.Y.; Fu, Y.C.; Chang, W.H.; Lo, W.W.; Lin, C.L.; Lo, Y.C. Triptolide prevents LPS-induced skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating protein synthesis/degradation pathway. Br. J. Pharmacol. 2021, 178, 2998–3016.

• 51.

  Bellanti, F.; Lo Buglio, A.; Vendemiale, G. Mitochondrial Impairment in Sarcopenia. Biology 2021, 10, 31.

• 52.

  Orlowski, G.M.; Sharma, S.; Colbert, J.D.; Bogyo, M.; Robertson, S.A.; Kataoka, H.; Chan, F.K.; Rock, K.L. Frontline Science: Multiple cathepsins promote inflammasome-independent, particle-induced cell death during NLRP3-dependent IL-1β activation. J. Leukoc. Biol. 2017, 102, 7–17.

• 53.

  Aluganti Narasimhulu, C.; Singla, D.K. Amelioration of diabetes-induced inflammation mediated pyroptosis, sarcopenia, and adverse muscle remodelling by bone morphogenetic protein-7. J. Cachexia Sarcopenia Muscle 2021, 12, 403–420.

• 54.

  Chen, Y.; Qian, Q.; Yu, J. Carbenoxolone ameliorates insulin sensitivity in obese mice induced by high fat diet via regulating the IκB-α/NF-κB pathway and NLRP3 inflammasome. Biomed. Pharmacother. 2019, 115, 108868.

• 55.

  Dauth, A.; Bręborowicz, A.; Ruan, Y.; Tang, Q.; Zadeh, J.K.; Böhm, E.W.; Pfeiffer, N.; Khedkar, P.H.; Patzak, A.; Vujacic-Mirski, K.; et al. Sulodexide Prevents Hyperglycemia-Induced Endothelial Dysfunction and Oxidative Stress in Porcine Retinal Arterioles. Antioxidants 2023, 12, 388.

• 56.

  Ram, C.; Gairola, S.; Verma, S.; Mugale, M.N.; Bonam, S.R.; Murty, U.S.; Sahu, B.D. Biochanin A Ameliorates Nephropathy in High-Fat Diet/Streptozotocin-Induced Diabetic Rats: Effects on NF-kB/NLRP3 Axis, Pyroptosis, and Fibrosis. Antioxidants 2023, 12, 1052.

• 57.

  Meier, D.T.; de Paula Souza, J.; Donath, M.Y. Targeting the NLRP3 inflammasome-IL-1β pathway in type 2 diabetes and obesity. Diabetologia 2025, 68, 3–16.

• 58.

  Marchetti, C.; Swartzwelter, B.; Gamboni, F.; Neff, C.P.; Richter, K.; Azam, T.; Carta, S.; Tengesdal, I.; Nemkov, T.; D'Alessandro, A.; et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc. Natl. Acad. Sci. USA 2018, 115, E1530–E1539.

• 59.

  Kono, H.; Kimura, Y.; Latz, E. Inflammasome activation in response to dead cells and their metabolites. Curr. Opin. Immunol. 2014, 30, 91–98.

• 60.

  Goh, J.; Behringer, M. Exercise alarms the immune system: A HMGB1 perspective. Cytokine 2018, 110, 222–225.

• 61.

  Venereau, E.; Casalgrandi, M.; Schiraldi, M.; Antoine, D.J.; Cattaneo, A.; De Marchis, F.; Liu, J.; Antonelli, A.; Preti, A.; Raeli, L.; et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 2012, 209, 1519–1528.

• 62.

  Nogueira-Machado, J.A.; Volpe, C.M.; Veloso, C.A.; Chaves, M.M. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert. Opin. Ther. Targets 2011, 15, 1023–1035.

• 63.

  Yang, H.; Wang, H.; Andersson, U. Targeting Inflammation Driven by HMGB1. Front. Immunol. 2020, 11, 484.

• 64.

  Tang, D.; Kang, R.; Cheh, C.W.; Livesey, K.M.; Liang, X.; Schapiro, N.E.; Benschop, R.; Sparvero, L.J.; Amoscato, A.A.; Tracey, K.J.; et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010, 29, 5299–5310.

• 65.

  Yang, H.; Liu, H.; Zeng, Q.; Imperato, G.H.; Addorisio, M.E.; Li, J.; He, M.; Cheng, K.F.; Al-Abed, Y.; Harris, H.E.; et al. Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Mol. Med. 2019, 25, 13.

• 66.

  Yang, K.; Cao, F.; Wang, W.; Tian, Z.; Yang, L. The relationship between HMGB1 and autophagy in the pathogenesis of diabetes and its complications. Front. Endocrinol. 2023, 14, 1141516.

• 67.

  Yang, T.; Wu, X.; Wang, X. HMGB1 regulates autophagy via TLR4/NF-κB signaling pathway in myocardial injury induced by coronary microembolization. Eur. J. Med. Res. 2025, 30, 943.

• 68.

  Tang, D.; Kang, R.; Livesey, K.M.; Cheh, C.W.; Farkas, A.; Loughran, P.; Hoppe, G.; Bianchi, M.E.; Tracey, K.J.; Zeh, H.J., 3rd; et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 2010, 190, 881–892.

• 69.

  Kim, Y.H.; Kwak, M.S.; Lee, B.; Shin, J.M.; Aum, S.; Park, I.H.; Lee, M.G.; Shin, J.S. Secretory autophagy machinery and vesicular trafficking are involved in HMGB1 secretion. Autophagy 2021, 17, 2345–2362.

• 70.

  Jia, T.; Zhang, X.; Li, L.; Jiang, X.; Wang, M. Relationship Between Serum HMGB1 and RAGE Levels and Restenosis in Type 2 Diabetes Mellitus Patients Complicated With Lower Extremity Vascular Disease: A Retrospective Study. Diabetes Metab. Syndr. Obes. 2025, 18, 315–325.

• 71.

  Herwig, M.; Sieme, M.; Kovács, A.; Khan, M.; Mügge, A.; Schmidt, W.E.; Elci, F.; Sasidharan, S.; Haldenwang, P.; Wintrich, J.; et al. Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features. Cardiovasc. Diabetol. 2025, 24, 203.

• 72.

  Sun, W.; Xu, J.; Li, S.; Zhao, Y.; Fu, J.; Di, L.; Han, D. GLUT1-mediated HMGB1 O-GlcNAcylation drives hyperglycemia-Induced neutrophil extracellular trap networks formation via TLR4 signaling and exacerbates fibroblast inflammation. Sci. Rep. 2025, 15, 18853.

• 73.

  Wu, H.; Ballantyne, C.M. Skeletal muscle inflammation and insulin resistance in obesity. J. Clin. Invest. 2017, 127, 43–54.

• 74.

  Muth, I.E.; Zschüntzsch, J.; Kleinschnitz, K.; Wrede, A.; Gerhardt, E.; Balcarek, P.; Schreiber-Katz, O.; Zierz, S.; Dalakas, M.C.; Voll, R.E.; et al. HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. Exp. Neurol. 2015, 271, 189–197.

• 75.

  Li, L.; Liu, H.; Tao, W.; Wen, S.; Fu, X.; Yu, S. Pharmacological Inhibition of HMGB1 Prevents Muscle Wasting. Front. Pharmacol. 2021, 12, 731386.

• 76.

  Ho, T.L.; Tang, C.H.; Chang, S.L.; Tsai, C.H.; Chen, H.T.; Su, C.M. HMGB1 Promotes In Vitro and In Vivo Skeletal Muscle Atrophy through an IL-18-Dependent Mechanism. Cells 2022, 11, 3936.

• 77.

  Fu, P.; Xu, H.; Gong, L. HMGB1: a key molecule linking chronic inflammation to complications in type 2 diabetes mellitus and a target for exercise intervention. Front. Endocrinol. 2026, 17, 1769497.

• 78.

  Shang, J.; Zhao, F.; Cao, Y.; Ping, F.; Wang, W.; Li, Y. HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis. BMC Mol. Cell Biol. 2023, 24, 2.

• 79.

  Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J.M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285, 248–251.

• 80.

  Yang, H.; Wang, H.; Ju, Z.; Ragab, A.A.; Lundbäck, P.; Long, W.; Valdes-Ferrer, S.I.; He, M.; Pribis, J.P.; Li, J.; et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J. Exp. Med. 2015, 212, 5–14.

• 81.

  Wang, Y.; Zhong, J.; Zhang, X.; Liu, Z.; Yang, Y.; Gong, Q.; Ren, B. The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes. J. Diabetes Res. 2016, 2016, 2543268.

• 82.

  Kong, X.; Lu, A.L.; Yao, X.M.; Hua, Q.; Li, X.Y.; Qin, L.; Zhang, H.M.; Meng, G.X.; Su, Q. Activation of NLRP3 Inflammasome by Advanced Glycation End Products Promotes Pancreatic Islet Damage. Oxid. Med. Cell Longev. 2017, 2017, 9692546.

• 83.

  Yu, M.; Wang, H.; Ding, A.; Golenbock, D.T.; Latz, E.; Czura, C.J.; Fenton, M.J.; Tracey, K.J.; Yang, H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006, 26, 174–179.

• 84.

  Kubat, G.B.; Bouhamida, E.; Ulger, O.; Turkel, I.; Pedriali, G.; Ramaccini, D.; Ekinci, O.; Ozerklig, B.; Atalay, O.; Patergnani, S.; et al. Mitochondrial dysfunction and skeletal muscle atrophy: Causes, mechanisms, and treatment strategies. Mitochondrion 2023, 72, 33–58.

• 85.

  Castillo Í, M.P.; Argilés, J.M.; Rueda, R.; Ramírez, M.; Pedrosa, J.M.L. Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved. Rev. Endocr. Metab. Disord. 2025, 26, 815–836.

• 86.

  Swanson, K.V.; Deng, M.; Ting, J.P.Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019, 19, 477–489.

• 87.

  Kelley, N.; Jeltema, D.; Duan, Y.; He, Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int. J. Mol. Sci. 2019, 20, 3328.

• 88.

  Liu, H.W.; Chang, S.J. Moderate Exercise Suppresses NF-κB Signaling and Activates the SIRT1-AMPK-PGC1α Axis to Attenuate Muscle Loss in Diabetic db/db Mice. Front. Physiol. 2018, 9, 636.

• 89.

  Pedersen, B.K.; Febbraio, M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 2012, 8, 457–465.

• 90.

  Li, Z.; Huang, Z.; Zhang, H.; Lu, J.; Tian, Y.; Piao, S.; Lin, Z.; Bai, L. Moderate-intensity exercise alleviates pyroptosis by promoting autophagy in osteoarthritis via the P2X7/AMPK/mTOR axis. Cell Death Discov. 2021, 7, 346.

• 91.

  Riahi, Y.; Wikstrom, J.D.; Bachar-Wikstrom, E.; Polin, N.; Zucker, H.; Lee, M.S.; Quan, W.; Haataja, L.; Liu, M.; Arvan, P.; et al. Autophagy is a major regulator of beta cell insulin homeostasis. Diabetologia 2016, 59, 1480–1491.

• 92.

  Vakili, O.; Klionsky, D.J.; Reiter, R.J.; Ren, J.; Deshpande, A.; Ahn, K.S.; Cho, W.C.; Hushmandi, K.; Kumar, A.P. Autophagy as a therapeutic linchpin in metabolic diseases and obesity-associated diabetes. Autophagy 2026, 22, 1444–1474.

• 93.

  Lee, Y.; Kim, J.H.; Hong, Y.; Lee, S.R.; Chang, K.T.; Hong, Y. Prophylactic effects of swimming exercise on autophagy-induced muscle atrophy in diabetic rats. Lab. Anim. Res. 2012, 28, 171–179.

• 94.

  Xiang, M.; Yuan, X.; Zhang, N.; Zhang, L.; Liu, Y.; Liu, J.; Gao, Y.; Xu, Y.; Sun, W.; Tang, Q.; et al. Effects of exercise, metformin, and combination treatments on type 2 diabetic mellitus-induced muscle atrophy in db/db mice: Crosstalk between autophagy and the proteasome. J. Physiol. Biochem. 2023, 80, 235–247.

• 95.

  Yang, L.; Lin, H.; Lin, W.; Xu, X. Exercise Ameliorates Insulin Resistance of Type 2 Diabetes through Motivating Short-Chain Fatty Acid-Mediated Skeletal Muscle Cell Autophagy. Biology 2020, 9, 203.

• 96.

  Hu, S.; Hu, Y.; Long, P.; Li, P.; Chen, P.; Wang, X. The effect of tai chi intervention on NLRP3 and its related antiviral inflammatory factors in the serum of patients with pre-diabetes. Front. Immunol. 2022, 13, 1026509.

• 97.

  Zhang, T.; Tian, J.; Fan, J.; Liu, X.; Wang, R. Exercise training-attenuated insulin resistance and liver injury in elderly pre-diabetic patients correlates with NLRP3 inflammasome. Front. Immunol. 2023, 14, 1082050.

• 98.

  Wei, H.; Cui, D. Pyroptosis and Insulin Resistance in Metabolic Organs. Int. J. Mol. Sci. 2022, 23, 11638.

• 99.

  Kar, S.; Shahshahan, H.R.; Hackfort, B.T.; Yadav, S.K.; Yadav, R.; Kambis, T.N.; Lefer, D.J.; Mishra, P.K. Exercise Training Promotes Cardiac Hydrogen Sulfide Biosynthesis and Mitigates Pyroptosis to Prevent High-Fat Diet-Induced Diabetic Cardiomyopathy. Antioxidants 2019, 8, 638.

• 100.

  Yan, X.; Fu, P.; Zhang, Y.; Ling, D.; Reynolds, L.; Hua, W.; Wang, Z.; Ma, F.; Li, B.; Yu, J.; et al. MCC950 Ameliorates Diabetic Muscle Atrophy in Mice by Inhibition of Pyroptosis and Its Synergistic Effect with Aerobic Exercise. Molecules 2024, 29, 712.

• 101.

  Schoenfeld, J.; Roeh, A.; Holdenrieder, S.; von Korn, P.; Haller, B.; Krueger, K.; Falkai, P.; Halle, M.; Hasan, A.; Scherr, J. High-mobility group box 1 protein, receptor for advanced glycation end products and nucleosomes increases after marathon. Front. Physiol. 2023, 14, 1118127.

• 102.

  Goh, J.; Hofmann, P.; Aw, N.H.; Tan, P.L.; Tschakert, G.; Mueller, A.; Wong, S.C.; Tan, F.; Gan, L.S.H. Concurrent high-intensity aerobic and resistance exercise modulates systemic release of alarmins (HMGB1, S100A8/A9, HSP70) and inflammatory biomarkers in healthy young men: a pilot study. Transl. Med. Commun. 2020, 5, 4.

• 103.

  Martinez Bravo, G.; Paramasivam, P.; Bellissimo, G.F.; Jacquez, Q.; Zheng, H.; Amorim, F.; Kovell, L.; Alvidrez, R.I.M. High-Intensity Interval Training Decreases Circulating HMGB1 in Individuals with Insulin Resistance: Plasma Lipidomics Correlate with Associated Cardiometabolic Benefits. Front. Biosci. 2025, 30, 31396.

• 104.

  Lee, H.M.; Kim, J.J.; Kim, H.J.; Shong, M.; Ku, B.J.; Jo, E.K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013, 62, 194–204.

• 105.

  Huo, L.; Liu, X.; Ding, N.; Zhang, H.; Hou, S.; He, J.; Zhao, B. Pyroptosis-Mediator GSDMD in Plasma: A Promising Biomarker for Early Diagnosis of Type 2 Diabetes. Diabetes Metab. Syndr. Obes. 2025, 18, 453–464.

• 106.

  Liu, T.; Zhao, H.; Wang, Y.; Qu, P.; Wang, Y.; Wu, X.; Zhao, T.; Yang, L.; Mao, H.; Peng, L.; et al. Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes. Front. Immunol. 2024, 15, 1334109.

• 107.

  Narasimhulu, C.A.; Singla, D.K. BMP-7 Attenuates Sarcopenia and Adverse Muscle Remodeling in Diabetic Mice via Alleviation of Lipids, Inflammation, HMGB1, and Pyroptosis. Antioxidants 2023, 12, 331.

• 108.

  Yang, J.; Wang, M.; Shi, L.; Fang, X.; Gao, C.; Ma, L.; Wang, Y.; Ying, S.; Yang, Y. The Stimulator of Interferon Genes Deficiency Attenuates Diabetic Myopathy Through Inhibiting NLRP3-Mediated Pyroptosis. J. Cachexia Sarcopenia Muscle 2025, 16, e13649.

• 109.

  Zhang, S.; Guo, S.; Wang, P.; Song, Y.; Yang, L.; Sun, Q.; Huang, Q.; Zhang, Y. Dapagliflozin attenuates skeletal muscle atrophy in diabetic nephropathy mice through suppressing Gasdermin D-mediated pyroptosis. Int. Immunopharmacol. 2025, 148, 114088.

• 110.

  Kim, Y.; Wang, W.; Okla, M.; Kang, I.; Moreau, R.; Chung, S. Suppression of NLRP3 inflammasome by γ-tocotrienol ameliorates type 2 diabetes. J. Lipid Res. 2016, 57, 66–76.

• 111.

  Mirza, R.E.; Fang, M.M.; Weinheimer-Haus, E.M.; Ennis, W.J.; Koh, T.J. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes 2014, 63, 1103–1114.

• 112.

  Wang, Y.; Zhu, X.; Yuan, S.; Wen, S.; Liu, X.; Wang, C.; Qu, Z.; Li, J.; Liu, H.; Sun, L.; et al. TLR4/NF-κB Signaling Induces GSDMD-Related Pyroptosis in Tubular Cells in Diabetic Kidney Disease. Front. Endocrinol. 2019, 10, 603.